Considering the huge differences of the expression between normal and myeloma cells, CD38 is thought to be a good drug target for cancer therapy10, 11, 12 and the human monoclonal antibody, daratumumab (DarzalexTM) has recently been approved by the US FDA13. The gene discussed is CD38; the disease is plasma cell myeloma.